AR and prostate carcinoma: Notably, the androgen receptor-independent transactivation of KHDC4 and TRAF2 by E2F4 was demonstrated using multiple prostate cancer cell lines (Supplementary Figures 7B and 8A) and further validated through clinically relevant transcriptome datasets (Supplementary Figure 8B).